Thrombopoietin Receptor Agonist Use in Children: Data from the Pediatric ITP Consortium of North America ICON2 Study

Cindy Neunert, MD MSCS1, Jenny Despotovic, DO MS2, Kristina Haley, DO MCR3, Michele P. Lambert, MD4, Kerri Nottage, MD5, Kristin Shimano, MD6, Carolyn Bennett, MD7, Robert Klaassen, MD FRCP8, Kimo Stine, MD9, Alexis Thompson, MD10, Yves Pastore, MD11, Travis Brown, BS12, Peter W. Forbes, MA12, and Rachael F. Grace, MD MMSc12 on behalf of the Pediatric ITP Consortium of North America (ICON)

1Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York, NY
2Texas Children’s Hematology Center, Baylor College of Medicine, Houston, TX
3Division of Pediatric Hematology/Oncology, Oregon Health and Sciences University, Portland, OR
4Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
5St. Jude Children’s Research Hospital, Memphis, TN
6Division of Pediatric Hematology/Oncology, University of California San Francisco, San Francisco, CA
7Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA
8Division of Pediatric Hematology/Oncology, University of Ottawa, Ottawa, Ontario
9Division of Pediatric Hematology/Oncology, University of Arkansas for Medical Sciences at Arkansas Children’s Hospital, Little Rock, AR
10Division of Hematology/Oncology, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
11CHU Ste-Justine, Montreal University, Montreal, Quebec
12Clinical Research Center, Boston Children’s Hospital, Boston, MA
13Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA

Corresponding Author: Cindy Neunert, MD MSCS, Address: 3959 Broadway, CHN 10-04, cn2401@cumc.columbia.edu, Phone: 212-342-3853, Fax: 212-342-5055.

Conflicts of Interest: CN, KS, YP, RG, KS, TB, JD, KH, JD, and PF have no conflicts of interest. RK- Amgen data monitoring committee for the Romiplostim 20080279 Study, chair of the bone marrow review panel for the Romiplostim study 20101221, and GlaxoSmithKline LLC data monitoring committee for Eltrombopag TRA108062 study. KN- employment with Janssen Research and Development. AP- research funding from Novartis, Amgen and Glaxo Smith Kline. CB- research funding from Amgen. ML- research funding from Glaxo Smith Kline and Astra Zeneca and consultant for Glaxo Smith Kline.
Abstract

Background—Data on second-line treatment options for pediatric patients with immune thrombocytopenia (ITP) are limited. Thrombopoietin receptor agonists (TPO-RA) provide a non-immunosuppressive option for children who require an increased platelet count.

Procedure—We performed a multi-center retrospective study of pediatric ITP patients followed at ITP Consortium of North America (ICON) sites to characterize TPO-RA use.

Results—Seventy-nine children had a total of 87 treatments (28 eltrombopag, 43 romiplostim, and 8 trialed on both). The majority had primary ITP (82%) and most (60.8%) had chronic ITP. However, 22% had persistent ITP and 18% had newly diagnosed ITP. During the first three months of treatment, 89% achieved a platelet count ≥ 50 × 10^9/l (86% romiplostim, 81% eltrombopag, p=0.26) at least once in the absence of rescue therapy. The average time to a response was 6.4 weeks for romiplostim and 7.0 weeks for eltrombopag (p=0.83). Only 40% of patients demonstrated a stable response with consistent dosing over time. An intermittent response with constant dose titration was seen in 15%, and an initial response that waned to no response was seen in 13%. Significant adverse events were minimal with the exception of two patients with thrombotic events and one who developed a neutralizing antibody.

Conclusions—Our results demonstrate that TPO-RA agents are being used in children with ITP of varying duration and severity. The response was similar to clinical trials, but the sustainability of response varied. Future studies need to focus on the ideal timing and rationale for these medications in pediatric patients.

Keywords

Immune Thrombocytopenia; Pediatrics; Treatment; Thrombopoietin Receptor Agonists; ICON

Introduction

Immune thrombocytopenia (ITP) is one of the most common conditions encountered by the pediatric hematologist. Current first-line therapy includes observation without drug therapy, corticosteroids, intravenous immune globulin, and anti-Rh(D) immunoglobulin[1, 2]. A minority of patients are refractory to first-line pharmacotherapy or develop chronic disease and require a second-line agent to improve health-related quality of life (HRQoL) and/or decrease bleeding symptoms. For pediatric patients who require second-line treatment, options include ongoing intermittent use of first-line agents, splenectomy, rituximab, or alternative immunosuppressive therapy.[1, 2] Each of these options carries a substantial risk and benefit profile that must be considered, and there remains a need for improved therapeutic approaches in these patients.

Recognition of impaired platelet production by megakaryocytes in patients with ITP led to the development of the thrombopoietin receptor agonists (TPO-RA).[3, 4] Two agents, romiplostim and eltrombopag, are currently FDA approved for adults with chronic ITP. Elnrombopag is also approved for children ≥1 year. Several clinical trials examining the efficacy of TPO-RAs in children with primary ITP have been published.[5-8] In a randomized phase I/II trial of pediatric patients with primary ITP for > 6 months, 88% of
patients receiving romiplostim maintained a platelet count > 50 × 10⁹/L for a median of 7 weeks compared to 0 patients in the placebo group.[5] Results from eltrombopag randomized clinical trials showed that approximately 40% of patients were able to achieve a platelet count ≥50 × 10⁹/L for the majority of study visits compared to 0 - 3% of patients in the placebo group. In the open-label phase of these trials, 80% of patients were able to achieve a platelet count ≥50 × 10⁹/L at least once.[6, 7] Additional data about the use of these agents in pediatric ITP is limited to small single center retrospective reviews and case series focused on children with persistent and chronic ITP.[9-11]

Despite a paucity of literature regarding TPO-RA use in children, physicians are prescribing TPO-RAs to pediatric patients off-label and outside of clinical trials. Furthermore, physicians may not be reserving these agents exclusively for chronic primary ITP, the only group in whom these agents have been investigated and are indicated. We present here multicenter retrospective data on TPO-RA administration to characterize the use of these agents in clinical practice.

Methods

Patient Sample

A retrospective chart review was performed at 12 sites in the Pediatric Immune Thrombocytopenia Consortium of North America (ICON). ICON is a research collaborative, wherein clinicians and researchers interested in pediatric ITP initiate and conduct collaborative studies. Boston Children’s Hospital serves as the coordinating study center.

The study was IRB approved at each site. Eligible patients were ages 0 to <18 years (y) treated with either eltrombopag or romiplostim between January 1, 2009 and November 31, 2014. Patients could have newly diagnosed, persistent, or chronic primary or secondary ITP. Patients were excluded if they were ever treated with a TPO-RA on a clinical trial or had non-immune thrombocytopenia.

Data Collection

Demographic and baseline ITP data were obtained. Information regarding TPO-RA initiation included the agent used, starting dose, platelet count at initiation, and reason for starting a TPO-RA. For each drug, information was collected on dosing, maximum dose, and platelet counts. Safety data focused on thrombosis, bone marrow reticulin, cataracts, and transaminitis (ALT > 3x normal). Discontinuation data included duration of TPO-RA use, reason for discontinuation, follow-up platelet counts, development of rebound thrombocytopenia (platelet count at or below baseline within 1 week of discontinuing TPO-RA), and status of ITP at both the time of discontinuation and data collection. Data were collected twice and patients are represented twice if they had been separately trialed on both agents.

Definitions

ITP status was classified using the international consensus guidelines as newly diagnosed (< 3 months), persistent (> 3 months and ≤12 months) and chronic (> 12 months).[12] The
baseline platelet count was the pretreatment value closest to the first dose of drug; which could represent recent additional therapy.

Platelet count response was defined two different ways to allow for comparison to other clinical trials. Consecutive response was a platelet count $\geq 20 \times 10^9$ above baseline for 2 consecutive weeks without requiring any new or increased concomitant ITP treatment. Single response was any platelet count $\geq 50 \times 10^9$/L without rescue therapy in the previous 7 days. The quality of response was described subjectively as stable, waned, or intermittent response with high variability in the platelet count. To verify integrity of this variable the platelet count response was reviewed by two independent authors (CN, RG, JD, ML, KN, KS, KH) for determination of response pattern. Thrombocytosis was defined as a platelet count $\geq 400 \times 10^9$/L.

**Statistical Methods**

Data were entered into REDCap and analyzed with SAS 9.3. For comparisons of the two drug regimens, the eight subjects who received both drugs were treated as independent. For continuous variables, the two drug regimens were compared using the Wilcoxon two-sample test. For categorical variables, Fisher’s exact test was used. Spearman correlations were used to test for association between patient age, starting dose, and highest dose achieved. Fisher’s exact test was used to compare reasons for starting TPO-RA treatment between the three ITP status groups (newly diagnosed, persistent, and chronic). T-tests were used to compare the ages of patients with and without physician concerns about low platelet count and to compare the ages of responders and non-responders. Fisher’s exact test was used to compare responders and non-responders on splenectomy status and ITP status (newly diagnosed, persistent, and chronic).

**Results**

A total of 79 patients were eligible for inclusion. Twenty-eight patients received only eltrombopag, 43 patients received only romiplostim, and 8 patients were trialed on both agents separately for a total of 87 treatments. Table I shows the demographic and baseline clinical data. Figure 1 shows the age distribution of TPO-RA use. Patients receiving romiplostim were significantly younger (romiplostim 10.9 y, eltrombopag 13.8 y; p=0.002), and patients with newly diagnosed ITP were more likely to be treated with romiplostim (13 romiplostim, 1 eltrombopag; p< .001). Fifteen children (19%) had secondary ITP including Evans syndrome (n=10), medication associated (n=1), Crohns disease (n=1), immunodeficiency (n=1) and multiple sclerosis (n=1). Although most children (61%) had chronic ITP at the time of TPO-RA initiation, 18% (n=14) had newly diagnosed ITP. All newly diagnosed patients had received additional therapies prior to starting a TPO-RA (median 3, range 1-6), including steroids (n=13), IVIG (n=14), splenectomy (n=3), and rituximab (n=5). At the time of last follow up (median length of follow up: 1.4 mo), 8 of the newly diagnosed patients continued to have active ITP, and 6 had resolved ITP.

The most important factors for initiating a TPO-RA are shown in Table II. Bleeding was a more common reason earlier in the ITP course with 93% of newly diagnosed, 47% of persistent, and 65% of chronic patients having bleeding symptoms listed as the reason for
starting (p=0.02). Physician concern as a reason for starting treatment was associated with younger age (concern: 9.7 y (SD 5.3); other: 12.9 y (SD 4.3), p=0.006). A goal platelet count was not stated in the chart for the majority of patients (n=49, 56%). For the 38 treatments in which a goal was stated, 7 had a goal of 100×10^9/l, 30 had a goal of 50×10^9/l, and 1 had a goal of 30×10^9/l.

**Dosing Data**

Fifty-one patients received romiplostim for a median of 6.3 mo (range 0.2 – 67.7) and 15 (29%) were still receiving drug at the conclusion of data collection. The median starting dose was 2 mcg/kg/week (range 1-9) and median highest dose achieved was 8 mcg/kg/week (range: 3 - 11). 35% of patients were escalated to the maximum dose of 10 mcg/kg/week, including 2 patients who received a dose of 11 mcg/kg/week. There was no association between patient age and starting dose or highest dose achieved. During the first 3 months of therapy, the median number of romiplostim dose adjustments was 5 (range 0-11) and the majority of patients were increased by 1 mcg/kg/week; however, 4 patients were increased by larger dose increments of 2-4 mcg/kg/week. Eight patients (16%) had received at least one dose of romiplostim at home.

Thirty-six patients received eltrombopag for a median of 7.4 mo (range 0.6-46.9) and 20 (56%) were still receiving drug at the end of data collection. The median starting dose was 50 mg/day (range 12.5-50 mg/day). The median highest dose achieved was 75 mg/day (range 50-125 mg/day). Seventy-two percent of patients were escalated to the highest dose of 75 mg/day, including one patient that received a maximum dose of 125 mg/day.

**Response Data**

Response data are shown in Table III. During the first three months of treatment, 71% of patients had a consecutive platelet count response and 84% had a single response. There was no difference in age, splenectomy status, or duration of ITP between responders and non-responders. Forty percent of patients demonstrated a stable response with fairly consistent dosing over time. There was no difference in response pattern between the two medications (p=0.59). The median platelet counts during the first 3 months of romiplostim and eltrombopag are shown in Figure 1. Nine patients experienced thrombocytosis (romiplostim= 2, eltrombopag=7; p=0.03). Thrombocytosis occurred 2-23 weeks after initiation and at doses ranging from 1-7 mcg/kg for romiplostim and 25-75 mg of eltrombopag. In the majority of cases, thrombocytosis was managed by holding or reducing doses or decreasing concomitant medications. In two cases, the thrombocytosis was associated with rescue medication administration.

Most patients on corticosteroids (21/30, 70%), taking 6-mercaptopurine (3/4, 75%), and all patients taking mycophenolate (n=3) were able to discontinue therapy during TPO-RA use. A total of 26 patients (10 eltrombopag, 16 romiplostim) suffered 40 bleeding events requiring rescue therapy. The most common rescue medications were corticosteroids and IVIg. The median time to first bleeding event was 7.4 weeks (range 0.1 – 125). Bleeding events requiring rescue therapy occurred at a median dose of 3 mcg/kg of romiplostim (range 0 – 11) and 50 mg of eltrombopag (range 12.5 – 75).
Discontinuation

Of the 87 patients on a TPO-RA, 54% (33 romiplostim, 14 eltrombopag p=0.03) discontinued the medication. TPO-RA was weaned in 32% and abruptly discontinued in 66%. Reasons for discontinuation were: lack of efficacy (32%), bridging to another agent (23%), spontaneous resolution of thrombocytopenia (17%), concern over frequency of labs and visits (n= 6, 13%), loss of response (13%), side effects (13%), and desire to know the baseline platelet count (9%). There were no subjects with reported rebound thrombocytopenia. From an intention to treat perspective, 5% (n=4) of all 79 treated patients demonstrated a documented durable response or remission once TPO-RA was discontinued.

Adverse Events and Surveillance

Objective adverse events included thrombosis (eltrombopag=2), development of a romiplostim neutralizing antibody (n=1). There were two pulmonary emboli (PE), which were not associated with thrombocytosis. One occurred in a 17-year-old female with persistent ITP two weeks after starting eltrombopag. She had undergone splenectomy at time of PE and had prothrombotic risk factors including post-operative state, obesity, concomitant steroid use, and oral contraceptive pill usage. Her platelet count was $60 \times 10^9/l$ at the time of the PE. The other PE occurred 3 months after switching from romiplostim to eltrombopag in a 17-year-old female with chronic ITP. Her platelet count was $61 \times 10^9/l$ two weeks prior to the PE. The neutralizing antibody was identified in a patient who did not attain a platelet count response following increasing romiplostim dose up to 10 mcg/kg. Neutralizing antibody was confirmed by testing performed by Amgen and the drug was withdrawn.

There were 53 (67%) patients who had at least one bone marrow biopsy performed (median= 1 bone marrow procedure each, range 1-4) for monitoring. Forty-seven (89% of the 53) were performed prior to or within 1 month of starting a TPO-RA. Of the 53 patients with bone marrow biopsies, 9 (17%) had increased bone marrow reticulin. Of the 9 children, 3 had increased reticulin noted prior to or within several days of starting treatment. Once reticulin was seen, annual follow up bone marrow biopsies were performed in 3 patients, drug was discontinued <6 months from the last bone marrow in 4 and the other 2 patients were lost to follow up. Of the patients on eltrombopag, there were no reported episodes of transaminitis. Seven (20%) patients on eltrombopag had an ophthalmology evaluation with none demonstrating cataract formation.

Discussion

We present the clinical use of the TPO-RAs, romiplostim and eltrombopag, in a large cohort of pediatric patients followed at 12 sites. Romiplostim is currently not FDA approved for use in pediatric ITP, and eltrombopag has a narrow indication for use in children ≥1 year of age who have chronic ITP. Our results highlight the diverse off-label use of these medications among tertiary care pediatric ITP practice sites in North America.

Current data on the use of TPO-RAs is limited to patients with chronic ITP, with only a few patients with persistent ITP represented in the PETIT study.[7] Patients with acute ITP represented nearly 20% of patients in our cohort, highlighting a subgroup of extremely
refractory newly diagnosed patients that failed first-line therapy with IVIg or corticosteroids, and in some case even splenectomy, early in their disease. Given high early spontaneous remission rates upwards of 75% in pediatric ITP, an important use for these agents might be as short-term therapy for early refractory disease where spontaneous remission is anticipated. Additionally, unlike adults, avoidance of immunosuppression and splenectomy is desirable as seen by the low number of children (n= 15) in our study cohort who had undergone splenectomy prior to TPO-RA use. Further information from clinical trials is needed to guide the ideal patient population for TPO-RA use in pediatrics, which may differ from the adult population due to these variables.

Overall, our data support that these agents are effective at increasing the platelet count similar to clinical trial results (supplemental Table I). Both agents had a comparable profile with regard to time to response and efficacy. We observed a consecutive response rate of 73% for romiplostim, which approximates the 88% from the phase I/II trial using a platelet count ≥50×10⁹/L on two consecutive weeks.[5] Similarly, we demonstrated a single response rate of 75% with eltrombopag; comparable to the 62% in the double blind phase and 80% in the open label phase of the PETIT studies.[6, 7] While there are a high number of responders based on platelet count, of the 79 treated patients, there were 21 (27%) that discontinued therapy because of either no response or a loss of response over time. An additional 12 patients (15%) discontinued because of the inconvenience of administration or side effects. Frequent dose modifications and waning responses were also frequently seen. Only 40% of patients demonstrated a stable platelet count and minimal dose changes of medication, which is similar to the complete response seen in children after treatment with rituximab[13] but significantly less than seen with splenectomy.[14-17] A subset of patients (13%) were identified who had a consecutive response initially, which waned over time. This type of individual response is not described in clinical trials and indicates that not all patients continue to respond with long-term use. These findings illustrate important differences between clinical trial and real world use.

Time to response and dosing data were also similar to clinical trials. The median romiplostim dose of 5 μg/kg at the time of response was identical to the median dose in the romiplostim randomized trial[5] and the dose of 52 mg for eltrombopag, prior to publication of pediatric dosing guidelines, was only slightly lower than the average dose of 63 mg in the PETIT2 double-blind phase.[6] While current dosing guidelines target a platelet count between 50- 200 × 10⁹/L, one benefit of these medications is the ability to titrate the dose to a desired platelet count. In our retrospective cohort, platelet count targets were often at the lower end of this range, which could reduce the therapeutic dose, provide cost saving strategies, and minimize side effects. Some patients in our study initiated drug at higher doses and had higher dose increases. It is possible that these strategies may result in a faster response time. In addition, frequent dose adjustment and monitoring may be avoided as we gain better understanding of the risks associated with temporary changes in the platelet count. Further investigation is needed to determine the ideal starting dose to maximize effectiveness, minimize side effects, and expand the use of these agents to the setting of acute bleeding events and for peri-procedural care.
We found there were few differences between patients receiving eltrombopag and romiplostim, except that patients receiving eltrombopag were significantly older, likely because our study period was prior to publication of the PETIT/PETIT2 studies [6, 7] that provided dosing data for pediatric patients and release of a liquid formulation. In selecting a TPO-RA, one consideration should be the route and location of administration. Romiplostim currently is not approved for home administration requiring weekly physician visits for the majority of children. However, this should be balanced against adherence with a daily medication and dietary considerations for eltrombopag administration. Providers should individually assess patients to determine which agent will align best with the patient and family preference and maximize adherence.

Across clinical trials these agents appear to be well tolerated and have an acceptable safety profile. We report here episodes of thrombotic events and the first report of neutralizing antibody formation in pediatric patients. The FDA currently recommends that patients on romiplostim experiencing failure to maintain a platelet response undergo neutralizing antibodies testing coordinated with the pharmaceutical company and drug discontinuation. There is no mention at this time regarding development of or testing for neutralizing antibodies against eltrombopag. In our cohort, there were an additional 6 patients who had an initial response to romiplostim that waned over time. It is not known if these patients had antibody formation testing. Bone marrow reticulin formation was an infrequent finding in our study. Obtaining reticulin stain on marrows prior to initiation of TPO-RA may prove helpful to effectively assess TPO-RA induced reticulin, as it can be present at baseline. No patients developed cataracts while receiving eltrombopag, but few patients underwent assessment for this adverse event or had baseline screening. Ophthalmology examinations might be difficult in centers with limited access to a pediatric ophthalmologist. In PETIT/PETIT2, two subjects developed cataracts, both had been treated with corticosteroids and one had pre-existing cataracts.[6, 7]

Our study is limited in its retrospective design. We are unable to comment on the impact of these agents on HRQoL or specifics regarding bleeding symptoms which may guide treatment decisions. Because retrospective assessment of bleeding severity is difficult we used need for rescue therapy as a surrogate. In clinical trials a consistent improvement in HRQoL has not been appreciated, possibly representing the burden of clinical trial participation. [7, 18] Since improved HRQoL was endorsed as a reason for initiating a TPO-RA, application of HRQoL measures both a priori and throughout treatment may provide useful information. Prospective trials collecting information on decision- making, HRQoL, and bleeding assessment are critically needed.

Our results represent patients on treatment for variable periods of time, making conclusions about long-term therapy difficult. For this reason, we focused much of our analysis on the first three months of therapy, which is similar to the initial time period of many clinical trials. However, this did not allow for monitoring of long-term side effects, an area still needing attention. All patients were treated at tertiary care referral sites, which may not be generalizable, however we feel it unlikely that refractory patients would be managed without referral to a pediatric hematologist. Our data did not allow for evaluation of adherence to medications or to dietary restrictions while taking eltrombopag which may impact response.
It is possible that some data are misclassified due to retrospective interpretation of medical documentation, for example the primary reason for starting a TPO-RA. Lastly, inherent to the landscape of trials in TPO-RAs, we subjectively defined response criteria. Supplemental Table I outlines the lack of uniformity in applying a standardize response criteria across both pediatric and adult trials[5-11, 19-36]. We therefore applied definitions common to the literature to allow for the best comparison between our data and the existing literature.

Our findings support that the TPO-RAs are effective at increasing the platelet count, at least temporarily, in the majority of patients, even those with newly diagnosed and secondary ITP. Benefits of the TPO-RAs include the ability to rapidly start and stop treatment and a desirable safety profile when compared to immunosuppressive treatments, such as rituximab and splenectomy. These benefits must be weighed alongside the cost of long-term use and patient and parent preferences. Consideration should be made to using these agents in newly diagnosed refractory patients as upfront bridging agents to remission and in secondary ITP. Future trials need to identify the population of pediatric patients who will benefit the most from the agents, novel dosing strategies to expand their use, and comparison of patient-related outcomes with other therapeutic options.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded by the Terrana fund for ITP research (Boston Children’s Hospital); and NIH K12 HL087164 grant funding (RG). The authors would also like to thank George Buchanan and Ellis Neufeld for their scientific and editorial input as well as all members of ICON.

References

Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015


**Abbreviation Key**

- **ITP**  Immune thrombocytopenia
- **TPO-RA**  Thrombopoietin receptor agonists
- **HRQoL**  Health-related quality of life
- **ICON**  Pediatric Immune Thrombocytopenia Consortium of North America
- **PE**  Pulmonary emboli

*Pediatr Blood Cancer. Author manuscript; available in PMC 2017 December 06.*
Figure 1.
Age distribution of children receiving TPO-RAs
Figure 2.
Median platelet counts during the first 3 months of romplostim (A) and eltrombopag (B)
Table I

Patient Demographics and Baseline ITP Data

<table>
<thead>
<tr>
<th></th>
<th>Total (n= 79)*</th>
<th>Romiplostim (n= 51)</th>
<th>Eltrombopag (n= 36)</th>
<th>p value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (mean, SD)</td>
<td>11.9, 4.8</td>
<td>10.9, 5.2</td>
<td>13.8, 3.4</td>
<td>0.002</td>
</tr>
<tr>
<td>Gender (Female)</td>
<td>50 (63.3%)</td>
<td>33 (64.7%)</td>
<td>22 (61.1%)</td>
<td>0.82</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>63 (79.7%)</td>
<td>41 (80%)</td>
<td>29 (81%)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>11 (13.9%)</td>
<td>5 (10%)</td>
<td>7 (19%)</td>
<td>0.08</td>
</tr>
<tr>
<td>Asian/Other</td>
<td>5 (6.3%)</td>
<td>5 (10%)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Ethnicity (Hispanic or Latino)</td>
<td>15 (19%)</td>
<td>10 (20%)</td>
<td>5 (14%)</td>
<td>0.29</td>
</tr>
<tr>
<td>Primary ITP</td>
<td>65 (82.3%)</td>
<td>42 (82%)</td>
<td>30 (83%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Baseline platelet count (median, range)</td>
<td>10 x 10^9/L, 0 - 258 x 10^9/L</td>
<td>10 x 10^9/L, 2 - 226 x 10^9/L</td>
<td>13 x 10^9/L, 0 - 258 x 10^9/L</td>
<td>0.68</td>
</tr>
<tr>
<td>Disease status at start of TPO-RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newly Diagnosed</td>
<td>14 (17.7%)</td>
<td>13 (25.5%)</td>
<td>1 (2.8%)</td>
<td>0.013</td>
</tr>
<tr>
<td>Persistent</td>
<td>17 (21.5%)</td>
<td>10 (19.6%)</td>
<td>9 (25%)</td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td>48 (60.8%)</td>
<td>28 (54.9%)</td>
<td>26 (72.2%)</td>
<td></td>
</tr>
<tr>
<td>Duration of ITP, months (mean, SD)</td>
<td>25.0, 29.4</td>
<td>20.7, 23.0</td>
<td>33.0, 35.2</td>
<td>0.07</td>
</tr>
<tr>
<td>Prior Splenectomy</td>
<td>15 (19%)</td>
<td>12 (23.5%)</td>
<td>3 (8.3%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Simultaneous ITP treatment at start of TPO-RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>28 (35%)</td>
<td>21 (42%)</td>
<td>9 (25%)</td>
<td>0.12</td>
</tr>
<tr>
<td>IVIg</td>
<td>23 (29%)</td>
<td>18 (35%)</td>
<td>7 (19%)</td>
<td>0.15</td>
</tr>
<tr>
<td>Rituximab</td>
<td>6 (8%)</td>
<td>6 (11%)</td>
<td>1 (3%)</td>
<td>0.23</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>3 (4%)</td>
<td>1 (2%)</td>
<td>2 (6%)</td>
<td>0.57</td>
</tr>
<tr>
<td>6-Mercaptopurine</td>
<td>3 (4%)</td>
<td>3 (6%)</td>
<td>1 (3%)</td>
<td>0.64</td>
</tr>
<tr>
<td>Dual TPO-RA use while switching</td>
<td>5 (0.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>7 (9%)</td>
<td>6 (12%)</td>
<td>5 (14%)</td>
<td>0.76</td>
</tr>
</tbody>
</table>

* includes 8 patients who received both romiplostim and eltrombopag.
† comparing romiplostim to eltrombopag
Table II

Initiation Data

<table>
<thead>
<tr>
<th>Reason for starting a TPO-RA</th>
<th>Total (n= 79)*</th>
<th>Romiplostim (n= 51)</th>
<th>Eltrombopag (n= 36)</th>
<th>p value+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding symptoms</td>
<td>29 (37%)</td>
<td>23 (45%)</td>
<td>9 (25%)</td>
<td>0.07</td>
</tr>
<tr>
<td>Failed other therapies</td>
<td>23 (29%)</td>
<td>14 (27%)</td>
<td>11 (31%)</td>
<td>0.81</td>
</tr>
<tr>
<td>Resume activities</td>
<td>8 (10%)</td>
<td>2 (4%)</td>
<td>7 (19%)</td>
<td>0.02</td>
</tr>
<tr>
<td>Improve health-related quality of life</td>
<td>6 (8%)</td>
<td>4 (8%)</td>
<td>3 (8%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Provider concern about low platelet count</td>
<td>5 (6%)</td>
<td>4 (8%)</td>
<td>1 (3%)</td>
<td>0.24</td>
</tr>
<tr>
<td>Avoid splenectomy</td>
<td>1 (1%)</td>
<td>1 (2%)</td>
<td>1 (3%)</td>
<td>0.49</td>
</tr>
<tr>
<td>Parental request</td>
<td>2 (3%)</td>
<td>0</td>
<td>2 (6%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Prior to surgical procedure</td>
<td>4 (5%)</td>
<td>3 (6%)</td>
<td>1 (3%)</td>
<td>0.34</td>
</tr>
</tbody>
</table>

* includes 8 patients who received both romiplostim and eltrombopag.

+ comparing romiplostim to eltrombopag
### Table III

Response Data

<table>
<thead>
<tr>
<th></th>
<th>Overall (N=87)</th>
<th>Romiplostim (n=51)</th>
<th>Eltrombopag (n=36)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consecutive response during the first 3 months</td>
<td>62 (71%)</td>
<td>37 (73%)</td>
<td>26 (72%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Average time (weeks) to consecutive response (mean, SD)</td>
<td>6.7 (10.4)</td>
<td>6.4 (9.8)</td>
<td>7.0 (11.4)</td>
<td>0.83</td>
</tr>
<tr>
<td>Average dose at time of consecutive response (mean)</td>
<td>n/a</td>
<td>5 mcg/kg</td>
<td>52 mg</td>
<td>n/a</td>
</tr>
<tr>
<td>Single response during the first 3 months</td>
<td>73 (84%)</td>
<td>44 (86%)</td>
<td>29 (81%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Subjective response</td>
<td>0.60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Responder with fairly consistent dosing over time</td>
<td>35 (40%)</td>
<td>24 (47%)</td>
<td>11 (30%)</td>
<td></td>
</tr>
<tr>
<td>Intermittent response with frequent dosing titration</td>
<td>12 (14%)</td>
<td>9 (17%)</td>
<td>3 (8%)</td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>11 (13%)</td>
<td>6 (12%)</td>
<td>5 (14%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Initial response that waned to no response over time</td>
<td>11 (13%)</td>
<td>6 (12%)</td>
<td>5 (14%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>15 (17%)</td>
<td>5 (10%)</td>
<td>10 (28%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>3 (3%)</td>
<td>1 (2%)</td>
<td>2 (6%)</td>
<td></td>
</tr>
</tbody>
</table>

*Other* responses included: response only in the setting of additional therapy (n=4, 5%); intermittent response with concerns about adherence (n=3, 4%); unable to assess due to a brief course or loss to follow-up (n=2, 2%); response only following splenectomy (n=2, 2%); intermittent response with consistent dosing (n=2, 2%); decline in platelet count with initiation (n=1, 1%); loss of response due to antibody formation (n=1, 1%)

+ comparing romiplostim to eltrombopag